News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bernstein Liebhard LLP has issued a shareholder class action alert against Molecular Partners AG (MOLN), reminding investors of the upcoming September 12, 2022 deadline to file a lead plaintiff motion. The lawsuit, filed in the United States District Court for the Southern District of …
Molecular Partners AG (0QXX) announced its Q4 2023 earnings, beating EPS and revenue expectations. The company reported an actual EPS of -CHF0.60 against a consensus of -CHF0.97, and actual revenue of CHF1.03M significantly surpassed the expected CHF400.00K. The next earnings report for Q2 2026 …
This article provides a valuation analysis of Molecular Partners AG (MOLN), focusing on its current valuation score, P/E ratio, and ranking within the Biotechnology & Medical Research industry. As of July 31, 2026, the company's valuation score is 7.34, ranking 184 out of 385, …
Sharemaestro market context Price below Trend Line 52 weeks +14.7%This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its volatility, financial risk, and investment risk. The company
Sharemaestro market context Price below Trend Line 52 weeks +14.7%This article provides a technical analysis of Molecular Partners AG (MOLN), detailing its current stock price momentum, support and resistance levels, and indicator readings. It shows that MOLN has a price momentum score of 2.98, trading between resistance at $4.10 and support at $3.64, …
Sharemaestro market context Price below Trend Line 52 weeks +14.7%This article provides a comprehensive overview of Molecular Partners AG (MOLN), including its current stock performance, key financial figures, and analyst ratings. The company, a Switzerland-based clinical-stage biotech firm, is developing DARPin therapeutics and is considered fairly valued with strong fundamentals. While analysts rate …
This article details the shareholder structure of Molecular Partners AG (MOLN), listing major shareholders such as Suvretta Capital Management, LLC and BVF Partners L.P., and categorizing shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity with specific changes …
This article provides a detailed quarterly and annual income statement for Molecular Partners AG (MOLN), allowing users to analyze its financial performance and operational efficiency. It covers various metrics including revenue, operating expenses, net income, and earnings per share over several fiscal periods. The …
This article provides a detailed cash flow statement for Molecular Partners AG (MOLN), presenting quarterly and annual financial data across operating, investing, and financing activities. It includes key figures such as net income, capital expenditures, and changes in working capital, along with year-over-year percentage …
This article presents a licensable picture from Reuters showing a representation of a DARPin at Molecular Partners in Schlieren, Switzerland. Molecular Partners is a biotech company specializing in custom-built DARPin therapeutics. The image was taken on May 28, 2026, by Denis Balibouse.
Molecular Partners (NASDAQ: MOLN) has announced the dosing of the first patients in its investigator-initiated Phase 2 TACTIC study for MP0317, an FAP-localized CD40 agonist. This randomized, multicenter trial in France will evaluate MP0317 in combination with standard-of-care chemoimmunotherapy for front-line advanced biliary tract …
Sharemaestro market context Price below Trend Line 52 weeks +14.7%Molecular Partners has announced clinical progress in its Phase 2 TACTIC trial for MP0317, a drug for advanced biliary tract carcinoma (cholangiocarcinoma). The randomized study, combining MP0317 with chemoimmunotherapy, is actively recruiting patients across nine sites in France, with a data update expected in …
Molecular Partners is presenting its bispecific Radio-DARPins at the Gordon Research Conference to address limitations in radioligand therapy. These innovative DARPins are designed to target multiple tumor sites simultaneously, enhancing precision and therapeutic effectiveness for heterogeneous cancers. The company's lead candidates, MP0712 and MP0726, …
Molecular Partners presented new data on its bispecific and multispecific Radio-DARPins at the Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer. The company is developing these Radio-DARPins to address tumor heterogeneity and engage multiple cancer targets simultaneously, aiming to improve precision …
Sharemaestro market context Price below Trend Line 52 weeks +14.7%Molecular Partners presented its bispecific Radio-DARPin approach to target tumor heterogeneity in cancer at the Gordon Research Conference. This innovative method aims to enhance radioligand therapy (RLT) by simultaneously engaging multiple tumor markers, thereby improving treatment precision and efficacy. The company's lead candidate, MP0712, …
Sharemaestro market context Price below Trend Line 52 weeks +14.7%Search by ticker symbol or company name and select a result to open its chart.